Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
European journal of dermatology : EJD - 31(2021), 1 vom: 01. Feb., Seite 98-99 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Komatsu-Fujii, Takayoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1548R74NSZ |
|---|
| Anmerkungen: |
Date Completed 03.11.2021 Date Revised 03.11.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1684/ejd.2020.3957 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321462807 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321462807 | ||
| 003 | DE-627 | ||
| 005 | 20231225175846.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1684/ejd.2020.3957 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321462807 | ||
| 035 | |a (NLM)33586655 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Komatsu-Fujii, Takayoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.11.2021 | ||
| 500 | |a Date Revised 03.11.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a tegafur-gimeracil-oteracil |2 NLM | |
| 650 | 7 | |a Tegafur |2 NLM | |
| 650 | 7 | |a 1548R74NSZ |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Oxonic Acid |2 NLM | |
| 650 | 7 | |a 5VT6420TIG |2 NLM | |
| 700 | 1 | |a Ogawa, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Nonoyama, Shoko |e verfasserin |4 aut | |
| 700 | 1 | |a Fukumoto, Takaya |e verfasserin |4 aut | |
| 700 | 1 | |a Tanabe, Hiroshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of dermatology : EJD |d 1996 |g 31(2021), 1 vom: 01. Feb., Seite 98-99 |w (DE-627)NLM091612039 |x 1952-4013 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:1 |g day:01 |g month:02 |g pages:98-99 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1684/ejd.2020.3957 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 1 |b 01 |c 02 |h 98-99 | ||